Biogenvs.Vertex Pharmaceuticals
BIIB vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 4.4× larger than Biogen by market cap; Vertex Pharmaceuticals trades at the lower P/E (30.7 vs 37.2); year to date, Biogen leads (+23.9% vs +20.8%).
Side by side
| BIIB | VRTX | |
|---|---|---|
| Market cap | $31B | $135B |
| Price | $220.77 | $552.85 |
| Today | +1.2% | +1.0% |
| Return YTD | +23.9% | +20.8% |
| Return 1Y | +56.6% | +38.6% |
| P/E | 37.2 | 30.7 |
| P/S | 3.1 | 10.7 |
| P/B | 1.6 | 6.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More BIIB & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.
See where BIIB and VRTX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →